
ãæ¬²ããããŒã¿ãã®ãŠã©åŽ
äœãèµ·ããŠããªãç¶æ³ã§ã¯ããããŒã¿ãéããããšããè¡åã«ã¯ã€ãªãããªãã§ããããããããŒã¿ãç©æ¥µçã«éããããšããããšã¯ããã®äºè±¡ãèµ·ããŠããŠãäºæ³ä»¥äžã«å¢ããŠããŠããããããã¯æ³å®å€ã®ç¶æ³ã«ãªã£ãŠããããã§ã¯ãªãã§ããããã
å¯åå¿çžè«ã»ã³ã¿ãŒããã®ããããåãã
ãã¬ãã®ãã¥ãŒã¹çªçµã§ãæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®å¯åå¿çãã§åãåããããããããããåãã«ããããšããäºäŸã玹ä»ãããŠããŸãããVol.6ã§åãäžããèå人ã®ãå®¶æã®å®äŸã§ãã
æ¥çš®ããæ¥ã«40âã®ç±ãåºãŠã2æ¥åŸã«å¯åå¿çžè«ã»ã³ã¿ãŒã«åãåãããããããã©ãããããããšããšèšãããããã®ç¿æ¥ã«ãè¿æã®ç
é¢ã«åãåããããšããããã€ãå»ãã¯ã¯ãã³ãæ¥çš®ããŠããç
é¢ãªã©ã«ãããåããåã³å¯åå¿çžè«ã»ã³ã¿ãŒã«åãåããããšããŸããããããããšããšèšãããããã£ãšç±ãäžããããç®èãã¯ãäžãã£ãŠããŠããŸã£ãã®ã§ãææ¥è»ã§æ¬éããç·æ¥å
¥é¢ã
çç¶ãªã©ã«ã€ããŠã¯ãVol.6ã§åãäžããŠããŸãã
å¯åå¿çžè«ã»ã³ã¿ãŒã¯ãã¡ãããšæ©èœããŠããã®ã§ãããããçªçµã§ã¯ããå¯åå¿çžè«ã»ã³ã¿ãŒã«é£çµ¡ãããããããåãã«ãããããšããäºäŸãåãäžããã®ã«ãçªçµå ã§ã³ã¡ã³ããæ±ããããå»åž«ã¯ãå¿é ãªçç¶ãåºãããå¯åå¿çžè«ã»ã³ã¿ãŒãããã®ã§ãããã«çžè«ããŠãã ããããšèšã£ãŠããŠãäœã®è§£æ±ºã«ããªã£ãŠããŸããã§ããã
æ±äº¬éœçŠç¥ä¿å¥å±ã®ãµã€ããèŠããšãå¯åå¿ã®çžè«ã«ã€ããŠã¯äžèšã®ããã«æžãããŠããŸãã
å€ãã¯2~3æ¥ã§ãããŸããŸãããæ¥çš®åŸã«æ°ã«ãªãçç¶ããã£ããããããã€ãå»ã«çžè«ããŸãããã
æ¥çš®åŸã«å¯åå¿ã®çç¶ãèŠãããå Žåãçè·åž«ãä¿å¥åž«çã«çžè«ã®ã§ããã³ãŒã«ã»ã³ã¿ãŒãèšçœ®ããŠããŸãã
ãŸãã¯ããããã€ãå»ã«çžè«ããããã«æžãããŠããŸããçžè«ã»ã³ã¿ãŒã¯ãäœãæããŠããããšãããªã®ã§ããããããããã€ãå»ãæããªã人ã¯ãæ¥çš®åŸã«äœãçç¶ãåºãããã©ããžè¡ãã°ããã®ã§ããããã
å¯åå¿çãã®å ±å矩å
ãã1ã€åé¡ãšãªã£ãŠããã®ããå¯åå¿çãã®å ±åã§ããå»åž«ããååŽçãžãå ±åãããã£ãŠããªãäŸãããããã§ããå»çæ©é¢ããã®å ±åã¯ãã©ã®ããã«ããŠè¡ãããŠããã®ã§ãããããååŽçã®ãµã€ãã«ã¯ãäžèšã®ããã«æžãããŠããŸãã
ååŽçãµã€ããããŒã > æ¿çã«ã€ã㊠> åéå¥ã®æ¿çäžèЧ > å¥åº·ã»å»ç > å¥åº· > ææçæ å ± > æ°åã³ãããŠã€ã«ã¹ææçã«ã€ã㊠> æ°åã³ããã¯ã¯ãã³ã«ã€ã㊠> æ°åã³ããã¯ã¯ãã³ã®æ¥çš®ãè¡ãå»çæ©é¢ãžã®ãç¥ãã > å»åž«çã®çããŸãžïœæ°åã³ããã¯ã¯ãã³ã®å¯åå¿çãå ±åã®ãé¡ãïœ
å ±åã®å¯Ÿè±¡ãšãªãçç¶ã®çºçãç¥ã£ããå»åž«åã¯å»çæ©é¢ã®éèšè ã¯ãäºé²æ¥çš®æ³ç¬¬12æ¡ã«åºã¥ããå ±åããªããã°ãªããªãããšãšãããŠããŸãã
â»ãæ¥çš®äŒå Žããå»çæ©é¢ã«æ£è ãæ¬éããå Žåãªã©ãè€æ°ã®å»åž«ã»å»çæ©é¢ãçç¶ã®çºçãç¥ã£ãå Žåããæ¥çš®ã®ç¶æ³ãçµéãªã©ã®æ å ±ãå¯èœãªç¯å²ã§ãŸãšããŠãããããã®å»åž«çãããå¿ ãå ±åãããããé¡ãããããŸãã
ãããããã®å»åž«ããšããæžãæ¹ã ãšãã誰ããå ±åããã ããããšæã£ãŠå ±åããªãå»åž«ãããã®ã§ã¯ãªãã§ãããããããã§ããçžè«ã®ãããåããšåããããªããšãèµ·ããå¯èœæ§ããããšæããŸãã
ã¡ãªã¿ã«ãäºé²æ¥ç𮿳ã«ã¯äžèšã®ããã«æžãããŠããŸãã
äºé²æ¥ç𮿳
(宿ã®äºé²æ¥çš®çãåããããšã«ãããã®ãšçãããçç¶ã®å ±å)
第åäºæ¡ãç é¢è¥ããã¯èšºçæã®éèšè åã¯å»åž«ã¯ã宿ã®äºé²æ¥çš®çãåããè ããåœè©²å®æã®äºé²æ¥çš®çãåããããšã«ãããã®ãšçãããçç¶ãšããŠåçåŽåç什ã§å®ãããã®ãåããŠããããšãç¥ã£ããšãã¯ããã®æšãåçåŽåç什ã§å®ãããšããã«ããåçåŽå倧è£ã«å ±åããªããã°ãªããªãã
ïŒãåçåŽå倧è£ã¯ãåé ã®èŠå®ã«ããå ±åããã£ããšãã¯ãé æ»ãªããåçåŽåç什ã§å®ãããšããã«ããããã®å 容ãåœè©²å®æã®äºé²æ¥çš®çãè¡ã£ãåžçºæé·åã¯éœéåºçç¥äºã«éç¥ãããã®ãšããã
ãã®å ±åã¯ãåžçºæé·ãéœéåºçç¥äºã«éç¥ãããåŸãã©ã®ããã«åŠçãããã®ã§ãããããç§ãã¡ã«ã¯ãã©ã®ããã«å ¬éãããã®ã§ãããããçãåžããã®å ±åã¯ããŸã èŠãããšããããŸããã
ããã«æ°ã«ãªãã®ããå ±åã®åºæºã§ãã
å ±åã®åºæº
å ±åã®å¯Ÿè±¡ãšãªãçç¶ã¯æ¬¡ã®éãã§ãã
âã¢ããã£ã©ãã·ãŒïŒã¯ã¯ãã³ãšã®é¢é£ã«ããããæ¥çš®åŸïŒæé以å ã«çºçããå Žåãå ±åã®å¯Ÿè±¡ã§ããïŒ
âå»åž«ãäºé²æ¥çš®ãšã®é¢é£æ§ãé«ããšèªããçç¶ã§ãã£ãŠã以äžã«è©²åœãããã®ïŒäºé²æ¥çš®ãšã®é¢é£æ§ãé«ããšå»åž«ãèªããæéã«çºçããå Žåãå ±åã®å¯Ÿè±¡ã§ããïŒ
ã»å ¥é¢æ²»çãå¿ èŠãšãããã®
ã»æ»äº¡ã身äœã®æ©èœã®é害ã«è³ããã®
ã»æ»äº¡è¥ããã¯èº«äœã®æ©èœã®é害ã«è³ããããã®ãããã® ã
ãå»åž«ãèªããããšããæžãæ¹ã§ã¯ãææ§ã§ããããã§ã¯ãå»åž«ãèªããªãã£ãããå ±åããªããŠãããããšã«ãªãã®ã§ã¯ãªãã§ããããã
ãã®äžã«ãããã«ç¶ããŠããŸãã
ã¯ã¯ãã³æ¥çš®ãšã®å æé¢ä¿ã瀺ãããŠããªãçç¶ãå«ããå¹ åºãè©äŸ¡ãè¡ããããåœé¢ã®éã以äžã®çç¶ã«ã€ããŠãå ±åãç©æ¥µçã«ãæ€èšãã ãããã
ãããããã®ã©ã³ã»ãã¬çåçŸ€ãæ¥æ§æ£åšæ§è³èé«çïŒADEMïŒãè¡å°æ¿æžå°æ§çŽ«æç ãè¡ç®¡çãç¡èæ§é«èçãè³çã»è³çãé¢ç¯çãèé«çãå¿ççãé¡é¢ç¥çµéº»çºãè¡ç®¡è¿·èµ°ç¥çµåå°ïŒå€±ç¥ã䌎ããã®ïŒ
äžèšã«ã€ããŠã¯ãç©æ¥µçã«å ±åããŠã»ãããšèšã£ãŠããŸãããšããããšã¯ãããããæ³å®å€ã«å¢ããŠãããšããããšãªã®ã§ã¯ãªãã§ãããããå¿ççã¯ãæµ·å€ã®äºäŸã§è¥è
ããã®å ±åãå¢ããŠãããšèšãããŠããŸãã
ã¢ã¡ãªã«CDCïŒçŸç
察çäºé²ã»ã³ã¿ãŒïŒã®ãµã€ãã«ãäžèšã®ãããªå ±åããããŸãã
Myocarditis and pericarditis after COVID-19 vaccination are rare. As of June 14, 2021, VAERS has received 511 reports of myocarditis or pericarditis among people ages 30 and younger who received COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults.
COVID-19ã¯ã¯ãã³æ¥çš®åŸã®å¿ççããã³å¿èçã¯ããŸãã§ãã2021幎6æ14æ¥ã®æç¹ã§ãVAERSã¯ãCOVID-19ã¯ã¯ãã³ãæ¥çš®ãã30æ³ä»¥äžã®äººã ã®éã§å¿ççãŸãã¯å¿èçã®511ä»¶ã®å ±åãåããŠããŸããã»ãšãã©ã®çäŸã¯ãmRNA COVID-19ã¯ã¯ãã³æ¥çš®ïŒãã¡ã€ã¶ãŒ-BioNTechãŸãã¯ModernaïŒã®åŸã«ãç¹ã«é幎æã®ç·æ§ãšè¥å¹Žæäººã§å ±åãããŠããŸãã
VAERSïŒVaccine Adverse Event Reporting SystemïŒã¯ãã¢ã¡ãªã«ã®CDCãéå¶ããŠããã¯ã¯ãã³å¯äœçšã¬ããŒãã§ããå¿ççã«ã€ããŠã詳ããã¯äžèšã®ããŒãžãèŠãããã«æžããŠãããŸãã
Since April 2021, there have been increased reports to the Vaccine Adverse Event Reporting System (VAERS) of cases of inflammation of the heartâcalled myocarditis and pericarditisâhappening after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna) in the United States.
These reports are rare, given the number of vaccine doses administered, and have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna), particularly in adolescents and young adults.
ã»Mostly in male adolescents and young adults age 16 years or older
ã»More often after getting the second dose of one of these two COVID-19 ãããã
ãvaccines than after the first dose
ã»Typically within several days after COVID-19 vaccination
Patients can usually return to their normal daily activities after their symptoms improve, and they should speak with their doctor about return to exercise or sports.
ãã€ã³ãããŸãšãããšã
ã»2021幎4æä»¥éãç±³åœã§mRNA COVID-19ã¯ã¯ãã³æ¥çš®ïŒPfizer-BioNTechããã³ModernaïŒåŸã«çºçãããå¿ççããã³å¿èçãšåŒã°ããå¿èã®ççã®çäŸã«é¢ããŠãVAERSãžã®å ±åãå¢ããŠããã
ã»ã¯ã¯ãã³ã®æäžåæ°ãèãããšãŸãã§ããã
ïŒç±³åœã§ã¯1å6500äžäººä»¥äžãCOVID-19ã¯ã¯ãã³ãå°ãªããšã1åæ¥çš®ïŒ
ã»äž»ã«é幎æã®ç·æ§ãš16æ³ä»¥äžã®è¥å¹Žæäººã«ãããŠå ±åãããŠããã
ã»æ£è
ã¯éåžžãçç¶ãæ¹åããåŸãéåžžã®æ¥åžžçæŽ»ã«æ»ãããšãã§ãããéåãã¹ããŒããžã®åŸ©åž°ã«ã€ããŠã¯ãå»åž«ã«çžè«ããå¿
èŠãããã
ãšããããšã§ãã
VAERSãžã®å ±åããã£ãæ°ãªã®ã§ãæ¬åœã«ãçšããšããããã¯ããããŸãããã¹ããŒããé 匵ã£ãŠããè¥è
ã«ãšã£ãŠã¯ãæ
éã«èããå¿
èŠããããããããŸããã
é¡é¢éº»çºã倱ç¥ãªã©ã¯ãVol.4ãšVol.18ã§åãäžããŠããŸãã
äºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠ
ããã»ã©ã®çªçµã§ã¯ãæ²»çè²»ææžå¶åºŠã«ã€ããŠã®ããããåãããåãäžããŠããŸãããã¯ã¯ãã³æ¥çš®åŸã«è
ã®çºããæ®ããç
é¢ã§å¯åå¿ãšèšºæã3é±éãã£ãŠãè
ã®çºããæ®ã£ãŠããã®ã§ãå¥åº·è¢«å®³ã®ææžå¶åºŠã䜿ãããã©ããåãåãããŠã¿ãããã§ãã
æ±äº¬éœïŒå¯åå¿çžè«ã»ã³ã¿ãŒïŒãäœãã§ããåºã«åãåãããŠãâæ°å®¿åºåœ¹æãæ
åœéšçœ²ã¯ãªãã®ã§çããããªããâååŽçãç³è«ã®åä»ã¯æ°å®¿åºãâæ°å®¿åºåœ¹æïŒè€æ°ã®éšçœ²ããããåãïŒâãã£ãšãããéšçœ²ãã¿ã€ããããç³è«ããŠã絊ä»ãŸã§ã«1幎ãããããšããããšèšããã
ããã§ã¯ã諊ããŠããŸã人ãã§ãŠããã§ããããšãåæãããæ¹ã¯è©±ããŠããŸããã
ååŽçã®ãµã€ãã«ã¯ãææžå¶åºŠã«ã€ããŠäžèšã®ããã«æžãããŠããŸãã
ååŽçãµã€ããããŒã > æ¿çã«ã€ã㊠> åéå¥ã®æ¿çäžèЧ > å¥åº·ã»å»ç > å¥åº· > ææçã»äºé²æ¥çš®æ å ± > äºé²æ¥çš®æ å ± > äºé²æ¥çš®å¥>å¥åº·è¢«å®³ææžã«ã€ããŠ>äºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠ
äºé²æ¥ç𮿳ã«åºã¥ãäºé²æ¥çš®ãåããæ¹ã«å¥åº·è¢«å®³ãçããå Žåããã®å¥åº·è¢«å®³ãæ¥çš®ãåããããšã«ãããã®ã§ãããšåçåŽå倧è£ãèªå®ãããšãã¯ãåžçºæã«ãã絊ä»ãè¡ãããŸããç³è«ã«å¿ èŠãšãªãæç¶ãçã«ã€ããŠã¯ãäºé²æ¥çš®ãåããããåžçºæã«ãçžè«ãã ãããïŒåçåŽå倧è£ã®èªå®ã«ããã£ãŠã¯ã第äžè ã«ããæ§æãããçŸç ã»é害èªå®å¯©æ»äŒã«ãããå æé¢ä¿ã«ä¿ã審æ»ãè¡ãããŸããïŒ
ãã®æµãã§ã¯ãæ¬åœã«1幎ãããããããããããŸããã
ææžå¶åºŠã«ã€ããŠã¯ããªãŒãã¬ãããå
¬éãããŠããŸãã
ãªãŒãã¬ããããåãã§ããïŒäºé²æ¥çš®åŸå¥åº·è¢«å®³ææžå¶åºŠã
ãã¯ã¯ãã³æ¥çš®ã«ããå¥åº·è¢«å®³ãšèªããããå Žåã«çµŠä»ãããŸãããšæžãããŠããã®ã§ã1å¹ŽåŸ ã£ãŠãèªããããªããã°ã絊ä»ã¯ãããªããšããããšã§ãã
ããæ°æ¥ã倧è£ãè€æ°ã®ãã¬ãçªçµã«åºæŒããŠãç©æ¥µçã«æ¥çš®ããŠãã ããããšèšã£ãŠããŸãããããããæ¥çš®ã¯ãé¡ããããã®ã§ã¯ãªãã¯ãã§ãã
ååŽçã®ãµã€ãã«ãããäºé²æ¥çš®ãåããæ¹ã«ã¯ãäºé²æ¥çš®ã«ããææçäºé²ã®å¹æãšå¯åå¿ã®ãªã¹ã¯ã®åæ¹ã«ã€ããŠçè§£ããäžã§ãèªãã®æå¿ã§æ¥çš®ãåããŠããã ããŠããŸãããšæžãããŠããŸãã
ãã¬ãåºæŒããŠæ¥çš®ããé¡ããããããæ¥çš®ããåŸã®ãã©ããŒäœå¶ãæŽããããšã®æ¹ãéèŠã§ã¯ãªãã§ãããããããšãçšã§ãã£ããšããŠããé節ãªå¯åå¿ãèµ·ããŠããããåãã«ããã人ãããã®ã§ãã

